$2.65
0.76%
Nasdaq, Oct 05, 04:00 pm EDT. Closed.
ISIN
US42328V5049
Symbol
HSDT

Helius Medical Technologies Inc Class A Stock price

$2.65
+0.41 18.30% 1M
+0.75 39.47% 6M
-0.24 8.30% YTD
-15.54 85.43% 1Y
-6,304.85 99.96% 3Y
-527,997.35 100.00% 5Y
-7,133,434.85 100.00% 10Y
-14,189,434.85 100.00% 20Y
Nasdaq, Closing price Mon, Oct 05 2026
+0.02 0.76%

Is Helius Medical Technologies Inc Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$159.0m
Enterprise Value
$132.1m
Net debt
positive
Cash
$27.0m
Shares outstanding
57.4m
Valuation
P/E
negative
P/S | estimate
13.2 | 12.9
EV/Sales | estimate
10.9 | 10.7
EV/FCF | ex SBC
negative | negative
P/B
0.9
Financial Health
Equity Ratio
99.0%
Return on Equity
-13.6%
ROCE
-13.9%
ROIC
-5,261.1%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$8.4m | 69.3%
SBC as % of FCF
-
SBC Growth 1Y
200.0%
Share Count Growth 1Y
8,344.1%
Shareholder Yield
-8,344.1%
Financials
Revenue | estimate
$12.1m | $12.3m
EBITDA
-
EBIT
$-24.2m
Net Income
$-157.3m
Free Cash Flow | ex SBC
$-26.9m | $-35.3m
Growth
Revenue | estimate
3,923.3% | 105.0%
EBITDA
-
EBIT
-66.3%
Net Income
-638.7%
Free Cash Flow
-135.5%
Margin
Gross
95.5%
EBITDA
-
EBIT
-200.5%
Net
-1,302.8%
Free Cash Flow | ex SBC
-223.2% | -292.5%
More
EPS
$-2.0
FCF per Share
$-0.5
Short interest
2.7%
Employees
21
Rev per Employee
$290.0k

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Helius Medical Technologies Inc Class A forecast:

Buy
88%
Hold
13%

Helius Medical Technologies Inc Class A Events

Past Events
AUG
14
Q2 2026 Earnings Call
about 2 months ago
MAY
15
Q1 2026 Earnings Call
5 months ago
MAR
30
Q4 2025 Earnings Call
6 months ago
NOV
18
Q3 2025 Earnings Call
11 months ago

Financial data from Helius Medical Technologies Inc Class A

Jun '26
+/-
%
12 12
3,923% 3,923%
100%
- Direct Costs 0.54 0.54
4% 4%
4%
12 12
4,535% 4,535%
96%
- Selling and Administrative Expenses 34 34
225% 225%
282%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
66% 66%
-201%
Net Profit -157 -157
639% 639%
-1,303%

In millions USD.

Don't miss a Thing! We will send you all news about Helius Medical Technologies Inc Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Helius Medical Technologies Inc Class A Stock News

Neutral
GlobeNewsWire
●
5 days ago
PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the Solana ecosystem, today announced that it has entered into a securities purchase agreement with a single institutional investor. The agreement provides for the purchase and s...
Neutral
GlobeNewsWire
●
about 2 months ago
PHILADELPHIA, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT), a listed digital asset treasury company and operator of institutional Solana validator infrastructure across Asia-Pacific, today announced its positions on the first three Solana Governance Proposals (SGPs) ahead of on-chain voting expected to open on 22 August 2026:
Neutral
GlobeNewsWire
●
about 2 months ago
PHILADELPHIA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the Solana ecosystem, today announced its results for the quarter ended June 30, 2026.
More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office United States
CEO Mr. Andreeff
Employees 21
Founded 2014
Website www.solanacompany.co

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today